Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05094336 · ClinicalTrials.gov registry record · Phase 1
A Study of AMG 193 in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
A Phase 1 study of Advanced MTAP-null Solid Tumors, sponsored by Amgen.
- Active
- Registry status
- Phase 1
- Development phase
- 329
- Enrollment target
- 20
- Study locations
NCT05094336 is a Phase 1 study of Advanced MTAP-null Solid Tumors that is active but no longer recruiting, run by Amgen. The registered enrollment target is 329 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT05094336, a Phase 1 study of Advanced MTAP-null Solid Tumors, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 329 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. The primary objective of Part 3 of this study is to evaluate the efficacy of AMG 193 in adult participants with metastatic or locally advanced MTAP-null solid tumors.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG AMG 193
- DRUG Comparator AMG 193 Test Tablet
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- California Research Institute - Glendale
- Fomat Medical Research - Oxnard
- University of California at SF - San Francisco
Indiana
- Goshen Health Systems - Goshen
- Indiana University - Indianapolis
- Community Health Network MD Anderson Cancer Center - North - Indianapolis
New York
- Roswell Park Cancer Institute - Buffalo
- Northwell Health Monter Cancer Center - Lake Success
- New York University Grossman School of Medicine and New York University Langone Hospitals - New York
Florida
- D and H Cancer Research Center - Margate
- Boca Raton Clinical Research Medical Center Inc - Tamarac
Maryland
- University of Maryland Medical Center - Baltimore
- American Oncology Partners, PA - Bethesda
Michigan
- Henry Ford Cancer Detroit (Brigitte Harris Cancer Pavilion) - Detroit
Missouri
- Washington University - St Louis
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 329 participants |
| Start Date | 2022-02-01 |
| Est. Completion | 2028-05-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05094336
The ClinicalTrials.gov registry entry for NCT05094336 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 329 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced MTAP-null Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which Docetaxel is the first listed.
NCT05094336 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Indiana, New York.
Frequently Asked Questions
What is clinical trial NCT05094336 about?
NCT05094336 is a clinical study titled "A Study of AMG 193 in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)". The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioad...
What is the current status of trial NCT05094336?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 329 participants. The study started on 2022-02-01. Estimated completion is 2028-05-30.
What conditions does trial NCT05094336 study?
This clinical trial studies the following conditions: Advanced MTAP-null Solid Tumors.
What interventions are being tested in trial NCT05094336?
The interventions under investigation include: Docetaxel (DRUG), AMG 193 (DRUG), Comparator AMG 193 Test Tablet (DRUG).
Who is sponsoring clinical trial NCT05094336?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05094336 being conducted?
This trial has 20 study locations across California, Florida, Indiana, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.